ArticleBioinformation2025
Melatonin as an adjuvant therapy in gestational hypertension and pre-eclampsia: A randomized controlled trial.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In spite of the improvement of obstetric care, hypertensive disorders of pregnancy have continued to emerge as the major causes of maternal and perinatal morbidity. Therefore, it is of interest to assess the effectiveness of melatonin as an adjuvant treatment in the management of gestational hypertension and pre-eclampsia in 404 pregnant women (183 taking melatonin and 221 taking standard care) in one of the tertiary care hospitals in India. Melatonin group also showed much lower incidences of serious pre-eclampsia that necessitated cesarean section (2.73% vs 8.60, p=0.014), lower rate of proteinuria (28.42 vs 37.10), and a better fetal outcome with a lower incidence of intrauterine death (4.92 vs 9.50). Melatonin supplementation is a potential adjuvant treatment that is promising to decrease the maternal and infant complications in pregnancy-related hypertension disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.